7,12-Dimethyl-6-benzanthrol | 60049-69-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 7,12-Dimethyl-6-benzanthrol
• 英文别名: Benz(a)anthracen-6-ol, 7,12-dimethyl-；7,12-dimethylbenzo[a]anthracen-6-ol
• CAS: 60049-69-6
• 化学式: C₂₀H₁₆O
• 分子量: 272.346
• InChiKey: BMVBOHOCDCRUHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  7,12-Dimethyl-5H-6-benzanthron 在 乙基磺酸 作用下， 以 乙腈 为溶剂， 生成 7,12-Dimethyl-6-benzanthrol
  参考文献：
  名称：

  K区芳烃氧化物的酸催化重排：酮中间体的观察和速率决定步骤的空间诱导变化

  摘要：

  K 区芳烃氧化物在乙腈中通过两个酸催化步骤重排为苯酚：将芳烃氧化物快速重排为 K 区苯酚的位置异构酮互变异构体，然后缓慢烯醇化。酮的积累是水溶液中芳烃氧化物的酸催化溶剂分解中提出的中间体，首次允许在溶剂分解条件下直接进行光谱观察和表征。报告了苯并 [a] 蒽的 K 区芳烃氧化物、其 1-、4-、7-、11-、12-甲基和 7,12-二甲基取代衍生物苯并 [a] 的速率常数和产物芘、苯并[c]菲、3-溴菲、屈、二苯并[a,h]蒽、菲和芘

  DOI：

  10.1021/ja00058a016

文献信息

• Multi-stage stem cell carcinogenesis
  申请人：Krtolica Ana

  公开号：US20100162416A1

  公开（公告）日：2010-06-24

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.
• [EN] MULTI-STAGE STEM CELL CARCINOGENESIS<br/>[FR] CARCINOGENESE DE CELLULES SOUCHES MULTIETAPES
  申请人：STEMLIFELINE INC

  公开号：WO2010037134A2

  公开（公告）日：2010-04-01

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.